Beta Bionics reported average baseline A1C of 9 among new iLet users, with roughly 70% switching directly from injections rather than other pumps. The company captured about 10% of the new patient insulin pump market by year-end 2025, underscoring expanding reach into both hard-to-manage and broader patient segments.

As of December 2025, Beta Bionics covered 63 U.S. sales territories and plans to add at least 20 additional territories in the first half of 2026. New territories typically generate incremental revenue within a quarter of representative hire, and leadership believes no additional field force expansion is needed to sustain growth.

The upcoming Mint patch pump, slated for commercialization by late 2027, features a two-part design with a reusable component for expensive electronics and a disposable three-day unit housing batteries, cannula and adhesive. The device will leverage the iLet learning algorithm and streamline change-out without phone re-pairing or recharging.

Beta Bionics’ bi-hormonal concept pairs automated insulin delivery with glucagon to reduce hypoglycemia risk and enable more aggressive glucose control. Exclusive glucagon rights support two Phase II trials this year, followed by a Phase III pivotal study requiring at least a year of drug exposure before potential commercialization.